FAB — Fusion Antibodies Share News
0.000.00%
Last trade - 00:00- £14.39m
- £14.53m
- £1.97m
Brief: Fusion Antibodies Says Cash Runway Into Q2 Of Calendar Year 2025
Fusion Antibodies - Trading update
Fusion Antibodies - New contract with existing client
RCS - Fusion Antibodies - Investor presentation
Brief: Fusion Antibodies Initiates Restructuring, Slashing Costs by 38% Including Headcount Reduction
Fusion Antibodies - Year-end trading statement
Fusion Antibodies - Contract to develop a bespoke OptiPhage library
Fusion Antibodies - Holding(s) in Company
Fusion Antibodies - Holding(s) in Company
Fusion Antibodies - Holding(s) in Company
Brief: Fusion Antibodies Raises £1,375,000
Fusion Antibodies - Grant of options and issue of shares to directors
Fusion Antibodies - Placing to raise £1,375,000
Fusion Antibodies - Follow-on project award and R&D update
Brief: Fusion Antibodies Gets R&D Tax Credit From HMRC For FY23
Fusion Antibodies - Director/PDMR Shareholding
Brief: Fusion Antibodies H1 Pretax Profit GBP -1.42 Mln
Brief: Fusion Antibodies Says Revenues For FY2024 Expected To Be Significantly Weighted Towards H2
Fusion Antibodies - Half-year Report